共查询到20条相似文献,搜索用时 187 毫秒
1.
《中华老年心脑血管病杂志》2015,(11)
目的构建人源性阿尔茨海默病(AD)噬菌体单链抗体(scFv)库,为筛选β淀粉样蛋白(Aβ1-42)的人源性特异性抗体奠定基础。方法采集18例AD患者的外周血40ml,提取总RNA,应用RT-PCR法得到人抗体可变区重链(VH)和可变区轻链(VL)基因。将VH和VL由连接肽连接得到scFv片段,将所得片段双酶切后,克隆至pCANTAB5E噬菌体载体,大肠埃希菌TG1感受态细胞经电击转化,辅助噬菌体M13K07拯救后构建scFv型噬菌体抗体库。结果总RNA经逆转录PCR扩增VH和VL可变区基因的凝胶电泳显示,PCR产物长度分别为360bp和300bp,其连接形成的scFv片段长度为750bp,最终构建了库容为2.4×109的scFv库。BstNⅠ酶切鉴定构建的scFv库,经凝胶电泳可见,酶切片段长度差异性大,显示scFv库具有良好的多样性。结论成功构建人源性AD噬菌体scFv库,为进一步筛选Aβ特异性抗体,继而为AD的治疗研究奠定基础。 相似文献
2.
人源化抗血小板膜糖蛋白Ⅱb/Ⅲa抗体库的构建及临床价值 总被引:2,自引:0,他引:2
目的筛选出抑制血小板聚集的血小板膜糖蛋白(GP)Ⅱb/Ⅲa自身抗体,用噬菌体表面展示技术构建人源化抗血小板GPⅡb/Ⅲa单链噬菌体抗体(ScFv)库。方法用单克隆抗体特异性俘获血小板抗原(MAIPA)技术和血小板聚集试验筛选出血浆中含有抑制血小板聚集的血小板GPⅡb/Ⅲa自身抗体的特发性血小板减少性紫癜(ITP)患者。从筛选出患者的外周血淋巴细胞中提取mRNA,用RT PCR扩增出人免疫球蛋白的重链可变区(VH)和轻链可变区(VL)基因片断,用DNA linker将VH和VL连接成ScFv基因片断。用限制性内切酶SfiⅠ/NotⅠ酶切ScFv后克隆到噬菌体载体pHEN2,然后转化大肠杆菌TG1。用辅助噬菌体M13K07援救转化后的TG1,产生ScFv。结果95例慢性ITP患者中41例(43.2%)血浆中抗GPⅡb/Ⅲa自身抗体阳性,强阳性患者5例(5.3%)。2例(2.1%)明显抑制血小板聚集功能。扩增出380~400bp大小的VH和VL基因,用连接肽(Gly4Ser)3成功地连接成约780bp大小的ScFv片断。ScFv克隆到pHEN2并转化大肠杆菌TG1后,形成2.1×107个克隆。用辅助噬菌体M13K07援救TG1后产生的噬菌体抗体库滴度为1.62×1010cfu/ml。结论少数抗GPⅡb/Ⅲa自身抗体可抑制血小板聚集功能。用噬菌体表面展示技术构建了ScFv库,可用来筛选人源化抗血小板GPⅡb/ⅢaScFv。 相似文献
3.
目的 构建人源性老年痴呆(AD)单链噬菌体抗体库,为进一步筛选AD相关抗原的人源性抗体奠定基础.方法 从200 ml AD病人的外周血中分离B淋巴细胞,提取总RNA,经逆转录合成总cDNA.以PCR技术,利用特定的引物分别扩增出人抗体的重链和轻链可变区基因片段(VH、VL),并分别克隆入噬菌粒pDAN5中,构建出含人单链抗体可变区(scFv)基因序列的pDAN5克隆载体,电转化感受态大肠杆菌XLI-Blue后,经辅助噬菌体M13K07超感染后回收全部重组噬菌体,构建成初级噬菌体抗体库.从抗体库中随机挑选数个克隆,提取质粒,PCR扩增目的片段后,用内切酶BstN Ⅰ消化,每个克隆经消化后的DNA指纹印迹用琼脂糖凝胶电泳分析,评价抗体库的多样性.结果 所有抗体VH和VL基因片段均得到了扩增并成功克隆及转化,经辅助噬菌体感染后,构建成初级抗体库.BstN Ⅰ消化后的DNA指纹图谱显示各克隆抗体基因各不相同,经计算构建的噬菌体抗体库容量为1.5×106.结论 利用噬菌体抗体库技术成功构建了AD病人的单链可变区噬菌体抗体库. 相似文献
4.
目的甲状腺自身免疫疾病(AITD)的患者血中有多种抗甲状腺自身抗体.为了构建单链抗体(ScFv)库以获得抗甲状腺ScFv,首先需要构建ScFv基因,我们利用重叠延伸拚接(SOE)法,制备了人源ScFv基因,为建立ScFv库和进一步研究AITD的发病机制及分析甲状腺自身抗体的作用打下基础.方法分离Graves病人血中的单个核细胞.提取总RNA,逆转录合成cDNA.参照文献报道设计引物,重链可变区(VH)和轻链可变区(VL)的引物均采用兼并序列引物,VH5′引物和VL3′引物带有27个互补碱基的接头(linker)编码序列.VL3′引物插入Spel内切酶位点,VH5′引物插入Sacl内切酶位点.先分别通过PCR扩增VH和VL,将纯化的VH和VL扩增产物按照一定比例混合,利用VH和VL互补序列,做15次PCR循环,合成出完整的ScFv基因,再以VH3′和VL5′引物进行PCR获得更多的ScFv基因产物,将ScFv基因重组到p3SCMH噬菌粒中,并做酶切鉴定.结果用PCR扩增VH和VL基因,PCR产物做电泳鉴定,经1.5%琼脂糖凝胶电泳,在380bp和420 bp左右有特异扩增带.将VH和VL的PCR产物用低溶点胶电泳纯化,并分别做DNA定量,将VH和VL的量调整为不同的比例做SOE,制备ScFv基因.PCR产物经1.5%琼脂糖凝胶电泳显示在800 bp左右有特异扩增带.纯化后的PCR产物,用Sacl+Spel双酶消化后,重组到噬菌粒中,转入XL1-blue大肠杆菌中扩增,再以提纯的重组噬菌粒做模板以VH3′引物和VL5′引物做PCR扩增,同时对重组噬菌粒做双酶切鉴定.琼脂糖凝胶电泳显示,两种鉴定方法均在800bp处有特异条带,证明ScFv连接成功.结论构建未知亲本抗体的ScFv常采用两种方法,一种是将Linker设计在表达载体上,两端各有限制性内切酶位点供VH和VL插入;另一种方法即本文使用的SOE法.前者操作繁杂,而SOE法虽然操作相对简单但不容易成功,它要求VH和VL的量要有严格的比例.由于纯化的VH和VL做准确定量有困难,我们的体会是做SOE时将VH和VL的量以不同的比例混合,以增加成功率.一般认为Linker长度以14~25个氨基酸残基为宜.本文采用的15肽序列(Gly4Ser)3是目前使用最广泛的Linker.本实验制备的ScFv基因已经成功的构建了噬菌体抗体库,并筛选出TRAb噬菌体抗体. 相似文献
5.
人源性抗-HBc单链噬菌体抗体库的构建 总被引:4,自引:0,他引:4
目的 构建人源性单链噬菌体抗体库,为筛选人源性抗—HBc单链抗体奠定基础。方法 利用逆转录—聚合酶链反应(RT—PCR)和噬菌体表面展示技术,直接从乙肝病毒核心抗体(抗—HBc)阳性患者淋巴细胞中提取总RNA,逆转录成cDNA;合成全套人抗体可变区引物扩增抗体可变区基因,并将重、轻链可变区基因进行拼接装配成单链抗体(ScFv)基因,重组于噬菌粒载体叶pHEN1,转化抑制型大肠埃希菌E.coliTG1,以辅助噬菌体援救后,构建成人源性单链噬菌体库。结果 成功地构建了人源性抗—HBc单链噬菌体库,库容量达10^6。结论 利用RT—PCR和噬菌体表面展示技术可以成功构建人源性单链抗体库,并达到建库标准,可进一步从中筛选人源性单链抗体。 相似文献
6.
将抗人肝癌单克隆抗体MD的重链可变区VH和轻链可变区VL基因重组,并使其表达。采用PT-PCR技术扩增VH及VL基因,通过重叠延伸拼接PCR在VH和VL基因间引入连接短肽,体外构建MDscFV基因,经过常规转化与筛选,诱导表达蛋白。MDscFV基因全长为732bp,VH354bp位于上游VL330bp位于下游。重组蛋白相对分子量36kDa。scFV保留了与亲本抗体MD相似的免疫活性。成功地构建了抗人单链抗体MDscFV,并获得了较高水平的功能性表达。 相似文献
7.
抗SSA噬菌体抗体库的构建及鉴定 总被引:1,自引:1,他引:1
目的 用噬菌体展示技术构建抗SSA单链抗体库。方法 分离抗SSA抗体阳性病人外周血单个核细胞 ,提取RNA并反转录cDNA。扩增免疫球蛋白重链可变区 (VH)和κ链可变区(Vκ)。通过重叠聚合酶链反应 (PCR)用连接片段将VH和Vκ体外连接成单链抗体 (single chainFv ,scFv)基因。而后用SfiⅠ和NotⅠ酶切并与噬菌粒 pHEN2 连接 ;将 pHEN2 scFv电转至大肠杆菌TG1,建立抗SSAscFvcDNA库。随机挑选克隆用PCR扩增插入片段了解插入效率。用辅助噬菌体VCS M13感染含 pHEN2 scFv的TG1,产生scFv噬菌体抗体。用酶联免疫吸附 (ELISA)检测构建的scFv噬菌体抗体库中有无抗SSA抗体存在。结果 与VH和Vκ支架结构互补的引物可扩增出 30 0~ 4 0 0bp大小VH和Vκ片断 ;重叠PCR体外连接成约 80 0bp大小scFv基因 (VH linker Vκ)。将scFv基因克隆至 pHEN2 ,电转TG1后计数克隆数为 3 0× 10 7cfu。随机挑选 12个克隆 ,其中 11个克隆PCR扩增出插入片段 ,插入效率约为 91%。用辅助噬菌体VCS M 13感染含 pHEN2 scFv的TG1后 ,产生 1 2× 10 14 pfu/ml噬菌体抗体颗粒。抗SSAELISA试剂盒检测其抗SSA活性 ,scFv噬菌体抗体的A值比相同稀释度的VCS M13的A值高 2 0~ 2 2倍。结论 建立的抗SSAscFv噬菌体抗体库含有的独立克隆数为 3 0× 10 相似文献
8.
丙型肝炎病毒核心蛋白人源单链可变区抗体的筛选与鉴定 总被引:15,自引:0,他引:15
目的 筛选、鉴定抗丙型肝炎病毒(HCV)核心蛋白的人源单链可变区抗体(ScFv)。方法 采用噬菌体表面展示技术,以重组的HCV核心蛋白为包被抗原,从噬菌体单链可变区抗体库中经过3轮“吸附-洗脱-扩增”筛选过程,获得抗原结合活性较强的HCV核心蛋白特异性人源单链可变区抗体片段阳性克隆,并对其进行免疫学及核苷酸序列测定。结果 筛选得到的ScFv片段具有抗HCV核心蛋白的特异性,基因序列分析结果表明符合人源单链可变区抗体基因序列的结构特征。结论 利用噬菌体抗体库技术,成功获得HCV核心蛋白的特异性人源单可变区抗体的编码基因。 相似文献
9.
目的 用基因工程抗体技术构建抗日本血吸虫膜蛋白特异的单链抗体。 方法 用抗体框架区的通用引物 PCR扩增抗日本血吸虫膜蛋白特异性单克隆抗体 NP11- 4的 VH 及 VL 基因 ,测序分析其核苷酸序列。用VH 和 VL 基因在 p THA90质粒载体中构建成单链抗体基因并诱导表达。 结果 扩增获得 NP11- 4的 VH 和 VL基因 ,经测序分析确定为新发现的抗体可变区序列 ,构建成排列顺序为 VH- linker- VL 的单链抗体基因 ,经诱导表达出与硫氧环蛋白融合的单链抗体 ,大小约为 36 .2 k Da,以包涵体形式存在。 结论 成功地构建和表达了抗日本血吸虫膜蛋白特异性单链抗体。 相似文献
10.
目的构建库容量大、多样性好的核糖体展示单链抗体库,为进一步筛选单链抗体奠定基础。方法对2006年10月1日至11月31日收集于中山大学附属第二医院的人外周血(健康成人2名,胃癌3例,肠癌3例,胰腺癌1例,每例各5mL,新生儿2名各2mL)分离淋巴细胞,提取RNA;利用RT-PCR克隆出全套重链可变区基因(variable region of heavy chain,VH)、轻链可变区基因(variable region of light chain,VL);然后利用重叠延伸PCR技术连接构建VH-VL单链抗体库。并通过连接T-Vector转化E.coli JM109大肠埃希菌,经蓝白筛选,挑取阳性克隆测序以鉴定单链抗体组装。结果试验成功构建了单链抗体核糖体展示模板,其库容达1.1×1013。结论大容量核糖体展示单链抗体库的构建为筛选多种人源性单链抗体奠定了基础。 相似文献
11.
12.
Wen WH Qin WJ Gao H Zhao J Jia LT Liao QH Meng YL Jin BQ Yao LB Chen SY Yang AG 《Journal of viral hepatitis》2007,14(7):512-519
Hepatitis B virus surface antigen (HBsAg), a specific antigen on the membrane of hepatitis B virus (HBV)-infected cells, provides a perfect target for therapeutic drugs. In order to mediate successful targeted delivery of these therapies, it is essential to have antibodies that recognize HBsAg with high specificity and affinity. In this report, we constructed a natural immune antigen binding fragments (Fab) antibody phage display library against HBsAg and after three rounds of panning, five Fab fragments with significant HBsAg binding ability were selected and analysed. DNA sequencing revealed that all the light chains had the same sequence, while all the Fd genes exhibited different sequences. For further application, all of the Fab antibodies were reconstructed into single chain antibodies (scFvs) and expressed in Escherichia coli BL21 cells. Indirect enzyme-linked immunosorbent assay analysis demonstrated that all five scFvs maintained a high affinity for HBsAg and could bind HBsAg on the membrane of HBV-infected cells. Indirect fluorescent staining analysis revealed that one of the scFvs (scFv15) could be internalized into HBsAg-positive HepG2.2.15 cells through clathrin-mediated endocytosis pathway. The internalizing scFv15 antibody would have great potential for the targeted delivery of therapeutics to HBV-infected cells. 相似文献
13.
Eren R Ilan E Nussbaum O Lubin I Terkieltaub D Arazi Y Ben-Moshe O Kitchinzky A Berr S Gopher J Zauberman A Galun E Shouval D Daudi N Eid A Jurim O Magnius LO Hammas B Reisner Y Dagan S 《Hepatology (Baltimore, Md.)》2000,32(3):588-596
Two human monoclonal antibodies (mAbs) against hepatitis B surface antigen (HBsAg) generated in the Trimera mouse system are described. Both mAbs 17.1.41 and 19.79.5 are of the IgG1 isotype and have high affinity constants for HBsAg binding in the range of 10(-10) mol/L. Monoclonal antibody 17.1.41 recognizes a conformational epitope on the a determinant of HBsAg whereas mAb 19.79.5 recognizes a linear one. The 2 mAbs bind to a panel of hepatitis B virus (HBV) subtypes with distinct patterns. The neutralizing activity of these antibodies was tested in 2 different animal model systems. Administration of each mAb to HBV-Trimera mice, a system that provides a mouse model for human hepatitis B infection, reduced the viral load and the percentage of HBV-DNA-positive mice in a dose-dependent manner. These 2 mAbs were more effective than a polyclonal antibody preparation (Hepatect; Biotest Pharma, Dreieich, Germany) in both inhibition of HBV liver infection and reduction of viral load. A single administration of a mixture of these mAbs into HBV chronic carrier chimpanzees resulted in immediate reduction in HBsAg levels followed by recurrence to initial levels within few days. Thus, these mAbs may be potential candidates for preventive therapy or in combination with other antiviral agents against HBV. Further studies in humans are needed to assess these mAbs in various clinical indications. 相似文献
14.
G McMahon P H Ehrlich Z A Moustafa L A McCarthy D Dottavio M D Tolpin P I Nadler L Ostberg 《Hepatology (Baltimore, Md.)》1992,15(5):757-766
A gene region encoding a segment of the major surface protein, HBsAg, of hepatitis B virus was analyzed from serum samples after orthotopic liver transplantation of three hepatitis B virus chronic carrier patients treated with a human anti-hepatitis B virus monoclonal antibody (SDZ OST 577). Each of these three patients became HBsAg negative after transplantation and therapy with the human anti-hepatitis B virus monoclonal antibody but returned to HBsAg positivity (first detected 143,251 and 252 days after the transplantation). Polymerase chain reaction DNA amplification was performed on DNA from serum samples showing low levels of recurrent HBsAg and reduced antigen reactivity with SDZ OST 577 antibody. Polymerase chain reaction DNA included a 230-bp highly conserved, major S gene region that was cloned into M13 bacteriophage; analysis of this DNA segment provided a consensus of DNA sequences for the serum samples exhibiting altered reactivity with the therapeutic monoclonal. Analysis of independent DNA clones from serum samples of patients exhibiting low but detectable recurrent serum levels of posttherapy HBsAg revealed the presence of S protein variant sequences when compared with polymerase chain reaction DNA derived from the original infected liver or pretherapy serum HBsAg. Genetic variation was predominant in a highly conserved peptide domain that has previously been implicated in antibody binding and neutralizing antibody epitopes. In independent patients infected with either adw or ayw hepatitis B virus subtypes, single nucleotide changes resulted in one to two amino acid differences for each variant allele (residues 124, 129, 131, 137, 140 and/or 145) when compared with pretherapy viral DNA. Administration of serum containing one of these variant viruses to a single hepatitis B-naive chimpanzee resulted in subclinical hepatitis and detectable levels of circulating anti-HBs and anti-HBc antibodies 49 and 70 days after virus administration, respectively. Hepatitis B virus DNA was recovered on liver biopsy between 6 and 8 wk after inoculation, although the animal remained persistently seronegative for HBsAg. DNA sequence analysis of both primate and patient liver hepatitis B virus confirmed the presence of the DNA encoding the S protein variant and associates this DNA with the predominant hepatotropic virus in liver infection. 相似文献
15.
S Ohkoshi 《Gastroenterologia Japonica》1991,26(6):728-733
The polymerase chain reaction (PCR) followed by Southern blotting was used to examine the presence of hepatitis B virus (HBV) DNA in non-cancerous liver tissue specimens from 22 Japanese hepatocellular carcinoma (HCC) patients, who were negative for HBV surface antigen (HBsAg). By Southern blot analysis, HBV DNA was negative in all 22 patients, but it was detected by the PCR in 8 of the 15 patients who were positive for antibodies against HBsAg or HBV core antigen. Seven patients who were negative for those antibodies were also negative for HBV DNA by the PCR. These results suggest that HBV may be involved in the etiology of the liver disease of some patients with what is presently classified as non-A, non-B hepatitis, if they are positive for HBV antibodies. 相似文献
16.
The hepatitis B surface antigen (HBsAg) is highly immunogenic and induces an antibody response which is protective in vivo against hepatitis B virus (HBV) infection. Human monoclonal antibodies specific for HBsAg were produced, which could have potential therapeutic applications. Lymphocytes obtained from a vaccinated donor were stimulated in vitro and fused with the human myeloma cell line GM 4672, and eight hybridomas were obtained. Three of these clones, which reacted in an ELISA against the HBsAg vaccine, were expanded, subcloned and further analyzed. The subclones E7C2, C4C10, and D5B2 were able to bind to different HBsAg preparations, which express various subtypes, and recognized the major HBsAg peptides in Western blot analysis. Cross-inhibition experiments showed that E7C2, C4C10 and D5B2 are directed against the same epitope and have an affinity constant ranging from 5 X 10(7) to 3.3 X 10(9) M. Furthermore, these antibodies stained the surface and cytoplasm of the HBsAg-secreting cell lines PLC/PRF/5 and 4.10. The production of immunoglobulins varies from 0.3 to 1.3 micrograms/ml/10(6) and has remained stable over a period of 8 months. These human monoclonal antibodies, which appear to be directed against an antigenic determinant common to all HBsAg subtypes, could be useful in the study of HBV-related liver diseases as well as in their diagnosis and experimental therapy. 相似文献
17.
Ge JH Liu HM Sun J Zhang LZ He J Li YL Liu H Xu Y Yu HY Hu YP 《World journal of gastroenterology : WJG》2004,10(21):3137-3140
AIM: To investigate the change of immunological characteristics of HBsAg caused by the mutation at codon 145 of HBsAg using DNA-based immunization. METHODS: Plasmids expressing mutant and wild type envelope antigens were transfected into human hepatocellular carcinoma cells via electrotransformation. The antigenicity of HBsAg was studied with EIA and immunocytochemical staining. Then plasmids were used to immunize 5 C57BL/6 mice. Sera of mice were detected for anti-HBs and anti-preS2 with ELISA. RESULTS: The mutant HBsAg could be detected by native antibody in EIA and immunocytochemical study. But the A((450 nm)) value of the mutant HBsAg in the supernatant was apparently lower than that of the wild-type. Both mutant and native HBsAg expression plasmid could stimulate a strong humoral immune response to HBsAg and preS2 antigen in mice. Protective antibodies against HBsAg elicited by the native HBsAg occurred earlier than that elicited by the mutant HBsAg about one to two weeks. The occurrence of protective antibodies against preS2 antigen was one to two weeks earlier than that of anti-HBs. CONCLUSION: The amino acid substitution causes changes of the antigenicity and immunogenicity of HBsAg, but mutant HBsAg can still induce a protective humoral immune response in mice. 相似文献
18.
Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen.
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
D Shouval J R Wands V R Zurawski Jr K J Isselbacher D A Shafritz 《Proceedings of the National Academy of Sciences of the United States of America》1982,79(2):650-654
High-affinity 125I-labelled monoclonal antibodies to hepatitis B virus surface antigen (HBsAg) bind to human hepatocellular carcinoma cell line, PLC/PRF/5, which synthesizes and secretes HBsAg. These monoclonal antibodies of the IgG1, IgG2a, and IgM isotypes are directed against different antigenic determinants on HBsAg and, in the presence of complement, both anti-HBs IgG2a and IgM, but not anti-HBs IgG1, lyse PLC/PRF/5 cells in culture. Although there is a low level of anti-HBs binding (especially with anti-HBs IgM) to human hepatoma cell lines which do not synthesize HBsAg (SK-Hep 1 and Mahlavu cells), this interaction does not lead to complement-mediated cell lysis and is thought to be nonspecific. Minimal binding of 125I-labeled anti-influenza HA antigen IgM binding to PLC/PRF/5 cells was also detected, but this likewise did not lead to complement-mediated cell lysis. These results indicate that a human hepatocellular carcinoma cell line, persistently infected with hepatitis B virus, can be recognized and lysed by monoclonal antibodies directed against specific determinants of HBsAg. Monoclonal antibodies to this viral envelope protein may prove to be useful immunodiagnostic and immunotherapeutic agents when such viral epitopes are expressed on the surface of infected cells. 相似文献
19.
Chen HB Fang DX Li FQ Jing HY Tan WG Li SQ 《World journal of gastroenterology : WJG》2003,9(2):304-308
AIM: Hepatitis B surface antigen (HBsAg) mutant of hepatitis B virus (HBV) is one of the important factors that result in immune escape and cause failure of immunization. In this study we reported and characterized a novel HBV mutant with A-to-G at nt551 and intended to provide theoretical data for prevention of HBV infection in China.METHODS: A methodology comprising polymerase chain reaction (PCR) amplifying, M13 bacteriophage cloning and nucleotide sequencing was used to analyze the sera of the pediatric patient who was hepatitis B (HB) immune failure.Expression plasmids containing the mutant S gene and a wild-type (adr) S gene were constructed respectively and the recombinant HBsAg were expressed in COS-7 cells under the regulation of SV40 early promoter. The recombinant proteins were investigated for their immunological reactivity with different monoclonal antibodies (mAb) against ‘a’determinant and vaccine-raised human neutralizing antibodies.RESULTS: It was found that there was a new point mutation at nt551 of the HBV (adr) genome from A to G, leading to a substitution of methionine (Met) to valine (Val) at position 133 in the ‘a’ determinant of HBsAg. Compared to the wildtype HBsAg, the binding activity of the muant HBsAg to mAbs (A6, All and S17) and to vaccine-raised human antihepatitis B surface antibody (anti-HBs) decreased significantly.CONCLUSION: According to the facts that the patient has been immunized with HB vaccine and that the serum is antiHBs positive and HBsAg negative, and based on the nucleotide sequence analysis of the mutant HBV S gene and its alteration of antigenicity, the HBV is considered to be a new vaccine-induced immune escape mutant different from the known ones. 相似文献
20.
乙型肝炎病毒表面抗原人源单链可变区抗体基因的克隆与鉴定 总被引:13,自引:0,他引:13
目的 筛选,鉴定抗乙型肝炎病毒(HBV)表面抗原(HBsAg)蛋白的人源单链可变区抗体(ScFv)的编码基因,为细胞内表达小分子单链抗体的研究及抗HBV的基因治疗研究奠定基础。方法 采用噬菌体表面展示技术,以氯化铯超速离心法纯化的HBsAg蛋白为固相抗原,从噬菌体单链可变区抗体半合成库中经过5轮“吸附-洗脱-扩增”淘洗过程,获得抗原结合活性较强的HBsAg人源单链可变区抗体阳性克隆,并对其进行免疫 相似文献